SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Marinaro Michael | EVP, Pres MedSurg and Americas | 2026-08-20 | Tax withholding | 1084 | $100K |
| Blomquist Denise L. | Chief Accounting Officer | 2026-08-03 | Grant/award | 2337 | $0 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | 2026-08-03 | Grant/award | 9230 | $0 |
| Marinaro Michael | EVP, Pres MedSurg and Americas | 2026-08-03 | Grant/award | 10960 | $0 |
| Marinaro Michael | EVP, Pres MedSurg and Americas | 2026-08-03 | Grant/award | 46147 | $0 |
| Martha Geoffrey | Chairman and CEO, Director | 2026-08-03 | Grant/award | 41533 | $0 |
| Pieton Thierry | EVP & Chief Financial Officer | 2026-08-03 | Grant/award | 11537 | $0 |
| Quinn Michelle | EVP, GC and Secretary | 2026-08-03 | Grant/award | 6346 | $0 |
| Thompson Kweli | EVP & President, Neuroscience | 2026-08-03 | Grant/award | 6923 | $0 |
| Walter Matthew R. | SVP, Chief HR Officer | 2026-08-03 | Grant/award | 5769 | $0 |
| Blomquist Denise L. | Chief Accounting Officer | 2026-07-31 | Tax withholding | 212 | $18K |
| KIIL HARRY SKIP | EVP & President Cardiovascular | 2026-07-31 | Tax withholding | 3074 | $262K |
| Marinaro Michael | EVP, Pres MedSurg and Americas | 2026-07-31 | Tax withholding | 3356 | $287K |
| Martha Geoffrey | Chairman and CEO, Director | 2026-07-31 | Tax withholding | 15810 | $1.4M |
| Thompson Kweli | EVP & President, Neuroscience | 2026-07-31 | Tax withholding | 1739 | $148K |
| Walter Matthew R. | SVP, Chief HR Officer | 2026-07-31 | Tax withholding | 1675 | $143K |
| Quinn Michelle | EVP, GC and Secretary | 2026-07-28 | Tax withholding | 2069 | $180K |
| Walter Matthew R. | SVP, Chief HR Officer | 2026-07-08 | Open-market sell 10b5-1 | 3102 | $258K |
| KIIL HARRY SKIP | EVP & President Cardiovascular | 2026-06-08 | Open-market sell | 3961 | $319K |
| KIIL HARRY SKIP | EVP & President Cardiovascular | 2026-06-08 | Open-market sell | 228 | $18K |
Fiscal period ending 2026-04-24 versus 2025-04-25 — view filing on EDGAR →
The risk profile has broadened materially, driven by the MiniMed separation and a simultaneous wave of new operational, regulatory, and litigation exposures. M&A execution risk is the dominant theme — concurrent transactions, separation costs, delayed synergies, and a planned further divestiture compound each other — while regulatory and reimbursement risks have expanded in scope and specificity. The single meaningful offset, removal of the IRS reclassification risk, is insufficient to counter the breadth of new worsening disclosures.
4 company-specific · 1 eased/removed · 3 common-mode
New disclosure of material separation risk: MiniMed IPO completed, 90% retained, further divestiture planned. Significant execution, cost, tax, and operational risks disclosed.
Risks Relating to the Proposed Separation of Our Diabetes Business The ongoing separation of our Diabetes Business could be delayed, may not be completed as currently contemplated, and could…
Revised language escalates execution risk: adds specific concerns about concurrent product launches, supply chain readiness, resource constraints, cost overruns, and competitive pacing of AI integration—substantive new operational and competitive risks.
Our success depends on our ability to differentiate our products and successfully execute and scale emerging technologies. Our continued growth and success depend on our ability to develop, acquire…
Added explicit risks: multiple simultaneous transactions straining resources, product approval/tariff hurdles, separation expenses, and earnings/cash flow pressure from transaction costs and delayed synergies.
Failure to identify, execute, and integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures and third-party…
Added specific operational risks: prior authorization, coverage variability, geographic payment differences, and delayed adoption impacts. Escalates reimbursement risk from compliance-focused to demand/adoption risk.
Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services, or changes to such laws, coverage policies, and payment practices, may subject us to…
Removal of material tax risk. Prior disclosure warned of potential IRS reclassification as U.S. corporation with substantially greater tax liability. Deletion suggests risk resolved or no longer material.
Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be…
New disclosure of government pricing controls, clawback arrangements, and site-of-service shifts materially escalating competitive and margin pressure.
Business and Operational Risks We operate in a highly competitive industry and we may be unable to compete effectively. We compete in both the therapeutic and diagnostic medical markets in more than…
Scope expanded from regulatory compliance focus to broader litigation and claims. New emphasis on third-party litigation funding, increased frequency/scope of claims, and management disruption.
We are subject to litigation, claims, investigations, and regulatory proceedings, which are inherently unpredictable and could materially adversely affect our business, results of operations…
Added explicit regulatory risks: data privacy, competition/antitrust compliance, and third-party vendor enforcement exposure. Expanded scope of regulatory obligations and enforcement risk.
Legal and Regulatory Risks We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and…
Medtronic issued a press release on September 1, 2026, announcing its first quarter fiscal 2027 financial results, including revenue of $9.8 billion (13.7% organic growth), GAAP diluted EPS of $1.14, and non-GAAP diluted EPS of $1.45. The company also raised its FY27 organic revenue growth guidance and non-GAAP EPS guidance. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's operational performance and forward guidance.
View raw filing on EDGAR →This is a clear earnings release disclosure under Item 2.02. The filing explicitly states that Medtronic issued a press release on June 3, 2026 announcing "full year and fourth quarter and fiscal year 2026 financial results," with the press release furnished as Exhibit 99.1. This is the standard format for earnings announcements and is material to investors assessing the company's financial performance.
View raw filing on EDGAR →